Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061652 | 0.84 | L3MBTL1 (0.56) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL30300530 | 0.84 | L3MBTL1 (0.56) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL5541680 | 0.79 | KDM4E (0.63) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL14330030 | 0.79 | GAA (0.59) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL19914273 | 0.77 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL23033213 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL353596 | 0.76 | POLB (0.48) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 | |
| SCHEMBL1655937 | 0.76 | ESR1 (0.58) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5542616 | 0.76 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2056293 | 0.76 | PIK3CG (0.61) | SMN1; SMN2ALDH1A1POLBGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205366-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | CARTHRONIX, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-06-02 | — | — | US | disclosed |
| US-10759764-B2 | Fluorination of organic compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200216449-A1 | 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method Therefor and Use Thereof | Tang, YaJie (CN) | 2020-07-09 | — | — | US | disclosed |
| WO-2019152731-A1 | ANDROGEN RECEPTOR ANTAGONISTS | ALPINE ANDROSCIENCES, INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152731-A1 | ANDROGEN RECEPTOR ANTAGONISTS | ALPINE ANDROSCIENCES, INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019056800-A1 | 4-SULFUR SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 汤亚杰 | 2019-03-28 | — | — | WO | disclosed |
| EP-2970158-B1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | BIOELECTRON TECH CORP (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| US-9540323-B2 | 7-hydroxy-indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006040646-A1 | BENZIMIDAZOLE OR INDOLE AMIDES AS INHIBITORS OF PIN1 | PFIZER, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20050222164-A1 | extra pyramidal syndrome, dystonia, restless leg syndrome or periodic limb movement in sleep; central nervous system diosrders; neurodegenerative diseases; attention deficit disorders; sedatives, antixiolytic and antiepileptic agents | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6897217-B2 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 813/4885ALDH1A1 892/4885POLB 2691/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SMN1; SMN2 3985/4885ALDH1A1 355/4885POLB 1637/4885 |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | PPOX, CYCS, SCO2 | SMN1; SMN2 4672/4885ALDH1A1 727/4885POLB 1118/4885 |
| US-20050222164-A1 | extra pyramidal syndrome, dystonia, restless leg syndrome or periodic limb movement in sleep; central nervous system diosrders; neurodegenerative diseases; attention deficit disorders; sedatives, antixiolytic and antiepileptic agents | DRD3, DRD2, SLC6A3 | SMN1; SMN2 680/4885ALDH1A1 1507/4885POLB 2657/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 837/4885ALDH1A1 591/4885POLB 2827/4885 |
| US-10759764-B2 | Fluorination of organic compounds | FLI1, SLCO2B1, SLCO1B3 | SMN1; SMN2 4597/4885ALDH1A1 142/4885POLB 2210/4885 |
| US-20200216449-A1 | 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method Therefor and Use Thereof | TPMT, WEE1, DHFR | SMN1; SMN2 4687/4885ALDH1A1 309/4885POLB 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.